Company profile

Anergis

Anergis proprietary Allergy Vaccines are designed to be safe and require treatment of only 2 months, in comparison to existing desensitization methods which require 3-5 years. By providing dramatic improvements in treatment safety, duration and convenience, with an equivalent or better long term efficacy, Anergis Breakthrough Allergy Vaccines will become a highly attractive alternative to all existing treatment options, with clear benefits to patients, doctors and health care players.

More news about Anergis

29.05.2020 08:14

Anergis on the way to a second-generation allergen immunotherapy

Please login or
register to use the
awards follow feature
12.09.2017 10:32

Trial of Anergis‘ ultra-fast allergy immunotherapy met all objectives

Please login or
register to use the
awards follow feature
04.04.2016 12:30

Anergis Closes CHF 5 Million Financing Round

Please login or
register to use the
awards follow feature
12.12.2014 08:42

Anergis Starts Phase II Dose Ranging Trial for Lead Vaccine

Please login or
register to use the
awards follow feature
03.12.2014 10:58

Anergis Closes Series B Financing Round Totaling CHF 14.5 Million

Please login or
register to use the
awards follow feature
07.02.2014 12:40

Anergis Closes Financing Round Totaling CHF 8 M

Please login or
register to use the
awards follow feature
27.09.2013 13:42

Anergis Winner of the Life Sciences Prize 2013

Please login or
register to use the
awards follow feature
12.09.2013 08:50

Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine

Please login or
register to use the
awards follow feature
13.06.2013 10:54

Anergis files patent on third product

Please login or
register to use the
awards follow feature
25.01.2013 13:53

Anergis Obtains U.S. Patent for Lead Product AllerT

Please login or
register to use the
awards follow feature
15.06.2012 15:31

Anergis Reaches Important Milestones with Second Product Candidate AllerR

Please login or
register to use the
awards follow feature
Anergis

Founded
2001

Kanton
VD

Homepage

rss